Pleuromutilin derivatives and their synthesis methods and applications
By designing and synthesizing truncated leptin derivatives with pyridine cationic structure, the resistance of multidrug-resistant bacteria to traditional antibiotics is solved, and the efficient inhibition and safety of multidrug-resistant bacteria is achieved, which significantly improves the antibacterial Treatment effect.
Patent Information
- Application Number
- CN202310217159.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-08
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2043-03-08
AI Technical Summary
Bacterial resistance leads to a reduction in the efficacy of traditional antibiotic treatments. Existing antibiotics are ineffective against multidrug-resistant bacteria, seriously threatening human and animal health.
The truncated leptin derivative with pyridine cationic structure was designed and synthesized. By modifying the C14 side chain, its antibacterial activity was enhanced, and it was screened for high-efficiency antibacterial activity against bacteria such as Staphylococcus aureus, pneumococcal and other bacteria.
This derivative showed significant inhibitory effect on multidrug-resistant bacteria, including MRSA and MRSE, and produced almost no resistance, had stable safety and rapid bactericidal ability, which was better than traditional antibiotics.
Smart Images

Figure CN116063227B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of pharmaceutical chemistry, in particular to pleuromutilin derivatives and synthesis methods and applications thereof. Background Art
[0002] Bacterial resistance refers to the situation where bacteria have reduced sensitivity to drugs or have developed a high degree of tolerance, which greatly reduces human's ability to prevent bacteria and the therapeutic effect of drugs. Drug-resistant bacteria pose a serious threat to human health. The drug-resistant bacteria we often talk about usually have multi-drug resistance. Multi-drug resistant bacteria refer to bacteria that are resistant to three or more classes of antibiotics at the same time. In order to pay attention to and guide research and development related to new antibiotics, the World Health Organization has published a list of pathogens that urgently need to develop new antimicrobial drugs, among which ESKAPE (Enterococcus faecalis, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter) pathogens are listed as priorities. Bacteria acquire drug-resistant genes through gene mutation and gene transfer. ESKAPE pathogens have developed resistance mechanisms to oxazolidinones, lipopeptides, macrolides, fluoroquinolones, tetracyclines, beta-lactams, beta-lactamase inhibitor combinations, and antibiotics as the last line of defense (including carbapenems, glycopeptides and polymyxins).
[0003] Antimicrobial agents have made an indelible contribution to the health of humans and animals. Antimicrobial agents are widely used in animal disease control, prevention and treatment, and play a vital role as growth promoters in animal husbandry. Several types of antimicrobial agents, such as antibiotics, disinfectants and food preservatives, can be used on microorganisms to reduce their growth ability, inhibit reproduction, or even kill them. Some natural, semi-synthetic and synthetic agents have unique mechanisms that can cause major changes at the metabolic and physiological levels, such as changes in cell wall synthesis by β-lactams and glycopeptides, inhibition of protein synthesis by macrolides and tetracyclines, inhibition of metabolic pathways by sulfonamides, and interference with DNA replication and translation by fluoroquinolones. Overuse and misuse of antimicrobial agents in livestock and poultry feed have led to a rapid increase in antimicrobial resistance. Multidrug resistance (MDR) has caused major economic and health problems, affecting animal husbandry and human healthcare, and leading to the failure of traditional clinical treatments. Antimicrobial resistance is a major threat to human and animal health.
[0004] Pleuromutilin was first discovered as a natural compound in 1951, and its crystalline form was isolated from cultures of two fungi (Pleurotus mutilus and P. passeckerianus). Through various stability tests, pleuromutilin was shown to be more stable than most antibiotics and has good antibacterial activity against Gram-positive bacteria. After the structure of pleuromutilin was elucidated, a series of new derivatives were synthesized through chemical modification to improve its antibacterial activity; the focus of the modification was on the C14 side chain.
[0005] With the in-depth study of the antibacterial mechanism of pleuromutilin, biosafety faces severe challenges in response to the increasingly serious problem of bacterial multidrug resistance. Based on existing research, this study redesigned pleuromutilin derivatives, screened pleuromutilin derivatives with good antibacterial activity, synthesized and evaluated their in vivo and in vitro antibacterial activities, and studied the antibacterial mechanism of a series of drugs; revealing the therapeutic potential of pleuromutilin derivatives as lead compounds for further optimization and discovery of new antibiotics. Summary of the invention
[0006] In order to make up for the deficiencies of the prior art, the present invention provides pleuromutilin derivatives and synthesis methods and applications thereof, redesigns the pleuromutilin derivatives, adds a pyridine group modification to the C14 side chain, and the pyridinium cation is expected to enhance the membrane permeability of pleuromutilin drugs; screens pleuromutilin derivatives containing pyridine side chains with good antibacterial activity, synthesizes and evaluates their in vivo and in vitro antibacterial activities, reveals the therapeutic potential of pleuromutilin derivatives as lead compounds for further optimization and discovery of new antibiotics, and solves the problems existing in the prior art.
[0007] The present invention is achieved through the following technical solutions:
[0008] One of the technical solutions provided by the present invention is:
[0009] A pleuromutilin derivative having the following general structural formula (I):
[0010]
[0011] Wherein, R is selected from one of the following alkyl chains, fatty acids, alcohols, ethers, and aromatic ring groups:
[0012] X is I or Br.
[0013] Furthermore, R is selected from one of the following groups:
[0014] Furthermore, R is X is 1.
[0015] The second technical solution provided by the present invention is:
[0016] A method for synthesizing the pleuromutilin derivative as described above comprises the following steps:
[0017] (1) Synthesis of pleuromutilin derivative intermediates
[0018] S1. Synthesis of intermediate b
[0019] Weigh pleuromutilin and add it to methyl tert-butyl ether, add 4-toluenesulfonyl chloride while stirring, add NaOH solution to the above solution to obtain a mixture; stir the above mixture at 60°C for 1 hour and then quickly cool it to 0°C to obtain a white suspension, wash it with methyl tert-butyl ether and water respectively, and dry it to obtain a white solid;
[0020] S2, synthesis of intermediate c:
[0021] Add 4-mercaptopyridine to a methanol solution, add NaOH to the above solution, stir at room temperature; add a dichloromethane solution containing compound b, stir at room temperature for 24 hours; adjust the solution pH to 6, concentrate under reduced pressure, add ethyl acetate to redissolve, add saturated sodium chloride to wash the extracted mixture, and dry it with anhydrous sodium sulfate; concentrate the organic phase, and purify it by column chromatography;
[0022]
[0023] (2) Synthesis of pleuromutilin derivatives e1-e29
[0024] 1 mmol of compound c and 1 mmol of linker RI were stirred and refluxed in 10 mL of acetonitrile solution. After the reaction was completed, the mixture was concentrated under reduced pressure, 10 mL of ethyl acetate was added to dissolve it again, saturated sodium chloride was added to wash and extract, and the mixture was dried over anhydrous sodium sulfate. The concentrated crude product was purified by column chromatography to obtain the product;
[0025]
[0026] Furthermore, the preparation operation of the mixture in step (1) is as follows: accurately weigh 7.57 g of pleuromutilin, add it to 25 mL of methyl tert-butyl ether, add 4.2 g of 4-toluenesulfonyl chloride while stirring, and add 5 mL of 10 M NaOH solution to the above solution to obtain a mixture.
[0027] Furthermore, in step (2), the amount of 4-mercaptopyridine used is 111 mg, the amount of methanol solution used is 1 mL; the amount of NaOH used is 40 mg; the amount of compound b used is 585 mg; and the amount of dichloromethane solution used is 3 mL.
[0028] The third technical solution provided by the present invention is:
[0029] The use of the pleuromutilin derivatives as described above in the preparation of antibacterial drugs.
[0030] The use of the pleuromutilin derivatives as described above in the preparation of drugs for preventing and / or treating multidrug-resistant bacterial infections.
[0031] Beneficial effects of the present invention:
[0032] The synthesis of the truncated pleuromutilin derivative of the present invention uses p-toluenesulfonyl chloride to activate the hydroxyl group at the C21 position of truncated pleuromutilin to produce an intermediate b, which then reacts with a nucleophilic reagent 4-mercaptopyridine to produce a key intermediate c under alkaline conditions. The intermediate c reacts with the side chain of the halogen to provide a pyridinium cation for the target molecule, and provides them with different hydrophilic units and electronic effects by changing the structure of the side chain end. The e1-e29 series of compounds are directly connected to the N4 of pyridine to obtain the pyridine structure of the target compound. Among them, compounds e4, e11, e12 and e27 show higher antibacterial activity against Staphylococcus aureus, pneumococcus, MRSA and MRSE than the existing tylosin. Through the study of the antibacterial mechanism, it is found that the series of derivatives can effectively interfere with the expression of bacterial proteins, among which e4 shows unique and excellent antibacterial activity, almost no drug resistance, and has stable safety. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 The time-killing curves of the compound e4 of the present invention against drug-resistant MRSA (A and B) and multidrug-resistant Staphylococcus aureus strains (C and D);
[0034] Figure 2 The drug resistance development of MRSA (A) and K.pneumoniae (B) after being induced by the compound e4 of the present invention for 24 days;
[0035] Figure 3 is the bacterial growth curve of MRSA (ATCC 43300) treated with different concentrations of the compound e4 of the present invention;
[0036] Figure 4 The ability of compound e4 of the present invention to inhibit the migration of six bacteria;
[0037] Figure 5 The effects of the compounds on a mouse model of systemic multidrug-resistant Staphylococcus aureus (S. aureus-sa1) infection;
[0038] Figure 6 The figure shows the effect of treating the lungs of infected mice with different concentrations of compound e4;
[0039] Figure 7The effect of the compound e4 of the present invention on the cell membrane morphology of Staphylococcus aureus ATCC 29213;
[0040] Figure 8 The antibacterial mechanism of compound e4 of the present invention against Staphylococcus aureus (ATCC 29213) is studied; scale bar: 25 μm;
[0041] Fig. 9 The effects of the compound e4 of the present invention and tiamulin on the proliferation of HEPG2 cells (A) and HEK293 cells (B) at different concentrations, the hemolytic activity of e4 (C), the inhibition of the production of hemolytic toxin of MRSA (ATCC43300) by e4 (D), and the acute toxicity test of e4 (E).
[0042] in, Figure 5 A and B in the figure respectively represent the effects of compound e4 and tiamulin on the systemic multidrug-resistant Staphylococcus aureus (S. aureus-sa1) infection mouse model; Figure 5 C and D show the bacterial load of Staphylococcus aureus in the lungs (C) and livers (D) of mice infected with different doses of e4 and tiamulin, respectively; **P < 0.05 was considered statistically significant;
[0043] Figure 6 A is the negative control group, B is the positive control group, C is the e4 40 mg / kg treatment group, D is the e4 20 mg / kg treatment group, E is the tiamulin 40 mg / kg treatment group, and F is the tiamulin 20 mg / kg treatment group (F);
[0044] Figure 7 AE: different concentrations of compound e4 co-cultured with Staphylococcus aureus, bar: 25 μ m; FJ: inhibitory effect of compound e4 on GFP Staphylococcus aureus ATCC 29213; bar: 25 μ m; K: release of β-galactosidase after co-culture with different concentrations of e4;
[0045] Fig. 9 A shows the effect of e4 and tiamulin on the proliferation of HEPG2 cells; B shows the effect of e4 and tiamulin on the proliferation of HEK293 cells; C shows the hemolytic activity of e4; D shows that e4 inhibits the production of hemolytic toxin of MRSA (ATCC43300); and E shows the acute toxicity test of e4. DETAILED DESCRIPTION
[0046] In order to clearly illustrate the technical features of this solution, the present invention is described in detail below through specific implementation methods and in conjunction with the accompanying drawings. The scope of the present invention is not limited to the following embodiments. Professionals in the field can understand that various changes and modifications can be made to the present invention without departing from the spirit and scope of the present invention.
[0047] The instruments, reagents, materials, etc. involved in the following embodiments, unless otherwise specified, are all conventional instruments, reagents, materials, etc. in the prior art and can be obtained through regular commercial channels. The experimental methods, detection methods, etc. involved in the following embodiments, unless otherwise specified, are all conventional experimental methods, detection methods, etc. in the prior art.
[0048] The synthesis method of the pleuromutilin derivative of the present invention is as follows:
[0049] 1. Synthesis method of pleuromutilin derivative intermediate
[0050] 1.1 Synthesis method of intermediate b:
[0051] Accurately weigh pleuromutilin (7.57 g, 20 mmol) and add it to 25 mL of methyl tert-butyl ether, add 4-toluenesulfonyl chloride (4.2 g, 22 mmol) while stirring, and add 5 mL of NaOH (10 M) solution to the above solution. The above mixture is stirred at 60°C for 1 hour and then rapidly cooled to 0°C. The obtained white suspension is washed with 3×10 mL of methyl tert-butyl ether and water respectively, and dried to obtain a white solid, which can be directly used in the next step without purification.
[0052] 1.2 Synthesis method of intermediate c:
[0053] Add 4-mercaptopyridine (111 mg, 1 mmol) to 1 mL of methanol solution, add 40 mg of NaOH to the above solution, and stir at room temperature for ten minutes. Add 3 mL of dichloromethane solution containing compound b (585 mg. 1.1 mmol) and stir at room temperature for 24 hours. Adjust the solution pH to 6, concentrate under reduced pressure, add 10 mL of ethyl acetate to dissolve again, add saturated sodium chloride to wash the extracted mixture, and dry it with anhydrous sodium sulfate. Concentrate the organic phase and purify it by column chromatography.
[0054] The synthetic reaction formula is as follows:
[0055]
[0056] 2. Synthesis of pleuromutilin derivatives e1-e29
[0057] The intermediate compound c (1 mmol) and the connecting group (1 mmol) were stirred and refluxed in 10 mL of acetonitrile solution. After the reaction was completed by monitoring by thin layer chromatography, the reaction solution was concentrated under reduced pressure, 10 mL of ethyl acetate was added to dissolve again, saturated sodium chloride was added to wash the extract, and dried over anhydrous sodium sulfate. The concentrated crude product was purified by silica gel column chromatography (dichloromethane: methanol = 100: 1-95: 5).
[0058] The synthetic reaction formula and the obtained compounds are as follows:
[0059]
[0060] All compounds were 1 H NMR, 13 The structures were identified by C NMR and LC-MS, and the structural characterizations are shown in the examples below.
[0061] Example 1
[0062] 4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propancyclopenten-5-yl)oxy)-2-oxoethyl)thio)-1-propylpyridin-1-ium (e1)
[0063] White powder, yield: 80%. 1 H NMR (600MHz, DMSO-d6) δ8.82(d,J=7.1Hz,2H),8.00(d,J=7.2Hz,2H),6.09(dd,J=17.8,11.2Hz,1H),5.58(d,J=8.3Hz,1H),5.07–4.97(m,2 H),4.57(d,J=6.1Hz,1H),4.41(t,J=7.2Hz,2H),4.38(d,J=2.9Hz,2H),3.42(t,J=6.1Hz,1H),2.42(s,1H),2.18(d,J=12.8Hz,1H),2.12–2 .01(m,3H),1.88(d,J=7.3Hz,2H),1.64(dd,J=23.2,12.4Hz,2H),1.49(d,J=3.8Hz,1H),1.42–1.35(m,1H),1.34(d,J=5.5Hz,3H),1.29(d, J=10.4Hz,1H),1.25(d,J=13.9Hz,2H),1.06(s,3H),1.04–0.99(m,1H),0.86(t,J=7.4Hz,3H),0.82(d,J=7.0Hz,3H),0.62(d,J=7.1Hz,3H).13 C NMR (150MHz, DMSO-d6) δ217.5,166.6,161.2,143.0,141.4,123.6,115.7,73.0,71.4,61.2,57.6,45.4,44.6 ,44.0,42.0,37.0,36.8,34.5,33.8,30.5,29.1,27.0,24.9,24.4,16.7,14.9,12.0,10.6.HRMS(ES)calcd[M] + for[C 30 H 44 NO4S + ]514.2991,found 514.2996.
[0064] Example 2
[0065] 4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanecyclopenten-5-yl)oxy)-2-oxoethyl)thio)-1-propylpyridin-1-ium (e2)
[0066] White powder, yield: 76%. 1 H NMR (600MHz, DMSO-d6) δ8.83(d,J=6.5Hz,2H),7.99(d,J=6.5Hz,2H),6.09(dd,J=17.7,11.1Hz,1H),5.58(d,J=8.2Hz,1H), 5.01(dd,J=26.7,14.5Hz,2H),4.57(d,J=5.9Hz,1H),4.44(s,2H),4.38(d,J=4.0Hz,2H),3.42(s,1H),2.42(s,1H),2.18(d ,J=10.8Hz,1H),2.13–2.01(m,3H),1.84(t,J=7.6Hz,2H),1.64(dd,J=24.4,12.7Hz,2H),1.50(s,1H),1.37(d,J=13.5Hz,1 H),1.33(s,4H),1.26(d,J=7.7Hz,4H),1.06(s,3H),1.01(s,1H),0.91(t,J=7.4Hz,3H),0.82(d,J=6.9Hz,3H),0.62(s,3H). 13C NMR (150MHz, DMSO-d6) δ217.5,166.6,161.2,143.0,141.4,123.7,115.7,73.0,71.4,59.7,57.6,45.4,44.6,44 .0,42.0,37.0,36.8,34.5,33.8,32.9,30.5,29.1,27.0,24.9,19.2,16.7,14.9,13.8,12.0.HRMS(ES)calcd[M] + for[C 31 H 46 NO4S + ]528.3147,found528.3143.
[0067] Example 3
[0068] 1-Butyl-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propylcyclopentadien-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e3)
[0069] White powder, yield: 70%. 1 H NMR (600MHz, DMSO-d6) δ8.84(d,J=6.5Hz,2H),7.99(d,J=6.7Hz,2H),6.09(d,J=6.6Hz,1H),5.58(d,J=8.2Hz,1H),5.01(dd,J =26.8,14.4Hz,2H),4.57(d,J=5.9Hz,1H),4.46(t,J=7.4Hz,2H),4.38(d,J=4.1Hz,2H),3.42(t,J=6.1Hz,1H),2.42(s,1H),2. 18(d,J=10.9Hz,1H),2.06(d,J=39.5Hz,3H),1.84(t,J=7.6Hz,2H),1.64(d,J=11.1Hz,2H),1.50(s,1H),1.36(s,1H),1.33(s ,3H),1.26(s,2H),1.25(s,2H),1.06(s,3H),1.00(s,1H),0.91(t,J=7.4Hz,3H),0.82(d,J=6.9Hz,3H),0.61(d,J=7.0Hz,3H). 13C NMR (150MHz, DMSO-d6) δ217.7,166.6,161.1,143.0,141.4,123.6,115.7,72.9,71.4,59.6,57.6,45.4,44.6,44 .0,42.0,37.0,36.8,34.5,33.7,32.9,30.5,29.1,27.0,24.9,19.2,16.7,14.9,13.8,12.0.HRMS(ES)calcd[M] + for[C 31 H 46 NO4S + ]528.3147, found 528.3143.
[0070] Example 4
[0071] 1-Heptyl-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-7-vinyldecahydro-4,9a-propylcyclopentadien-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e4)
[0072] Yellow powder, yield: 48%. 1 H NMR (600MHz, DMSO-d6) δ8.82(d,J=7.1Hz,2H),7.99(d,J=7.2Hz,2H),6.09(dd,J=17.8,11.2Hz,1H),5.58(d,J=8.3Hz,1H),5.07–4.96(m,2H),4.58(d, J=6.0Hz,1H),4.44(t,J=7.2Hz,2H),4.38(d,J=2.5Hz,2H),3.42(t,J=6.1H z,1H),2.40(s,1H),2.22–2.16(m,1H),2.12–2.01(m,3H),1.85(t,J=7.6Hz, 2H),1.68–1.59(m,2H),1.49(d,J=3.8Hz,1H),1.37(d,J=11.7Hz,1H),1.33 (d,J=6.6Hz,3H),1.31(s,1H),1.28(s,2H),1.26(s,2H),1.24(d,J=3.2Hz, 2H),1.23(s,2H),1.21(dd,J=14.5,6.4Hz,2H),1.06(s,3H),1.01(d,J=4.3 Hz,1H),0.86(t,J=7.0Hz,3H),0.82(d,J=7.0Hz,3H),0.61(d,J=7.1Hz,3H).13 C NMR (150MHz, DMSO-d6) δ217.5,166.6,161.2,143.0,141.3,123.7,115.7,73.0,71.4,59.9,57.6,45.4,44.6,44.0,42.0 ,37.0,36.8,34.5,33.7,31.5,30.9,30.5,29.2,28.5,27.0,25.8,24.9,22.4,16.7,14.9,14.4,12.0.HRMS(ES)calcd[M] + for[C 34 H 52 NO4S + ]570.3617, found 570.3613.
[0073] Example 5
[0074] 1-Decyl-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-7-vinyldecahydro-4,9a-propylcyclopentadien-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e5)
[0075] White powder; yield: 46%. 1 H NMR(600MHz,DMSO-d6)δ8.83(d,J=6.6
[0076] Hz,2H),8.00(d,J=6.6Hz,2H),6.09(dd,J=17.8,11.1Hz,1H),5.58(d,J=8.3Hz,1H),5.06–4.97(m,2H),4.59(d,J=6.0Hz,1H),4.44(t,J=7.2H z,2H),4.38(d,J=2.9Hz,2H),3.42(t,J=6.0Hz,1H),3.39(d,J=7.0Hz,1H),2.41(s,1H),2.18(d,J=11.0Hz,1H),2.13–2.04(m,2H),2.04–1.98( m,1H),1.93–1.77(m,2H),1.64(dd,J=24.2,12.8Hz,2H),1.49(d,J=10.1Hz,1H),1.39(t,J=13.9Hz,1H),1.34(d,J=7.2Hz,3H),1.32(s,1H),1 .27–1.22(m,14H),1.10(s,1H),1.06(s,3H),1.00(dd,J=16.9,5.8Hz,1H),0.86(t,J=6.9Hz,3H),0.82(d,J=6.8Hz,3H),0.61(d,J=7.1Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.5,166.6,161.1,143.0,141.3,123.6,115.7,72.9,71.4,65.4,59.9,57.6,55.4,45.4,44.6,44.0,42 .0,37.0,36.8,34.5,33.7,31.7,30.9,29.3,29.3,29.1,28.8,27.0,25.8,24.9,22.6,16.7,14.9,14.4,12.0.HRMS(ES)calcd[M] + for[C 37 H 58 NO4S + ]612.4081,found612.4085.
[0077] Example 6
[0078] 1-Dodecyl-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-7-vinyldecahydro-4,9a-propylcyclopentadien-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e6)
[0079] White powder;yield:52%. 1 H NMR(600MHz,DMSO-d6)δ8.82(d,J=5.6
[0080] Hz,2H),7.99(d,J=7.2Hz,2H),6.09(dd,J=17.8,11.2Hz,1H),5.58(d,J=8.3Hz,1H),5.04(d,J=17.8Hz,1H),4.99(d,J=12.9Hz,1H),4.58(d,J=6.1Hz,1H),4.44(d,J=7.2Hz,2H),4.38(d,J=2.8Hz,2H),3.42(t,J=5.9Hz,1H),2.41(s,1H),2.24–2.17(m,1H),2.12–2.01(m,3H),1.85(p,J=7.3Hz,2H),1.69–1.59(m,2H),1.49(q,J=4.4,3.6Hz,1H),1.36(s,1H),1.33(s,3H),1.31(d,J=6.3Hz,1H),1.30–1.18(m,20H),1.06(s,3H),1.04–0.99(m,1H),0.86(t,J=7.0Hz,3H),0.82(d,J=7.0Hz,3H),0.61(d,J=7.1Hz,3H). 13 C NMR(150MHz,DMSO)δ217.1,166.2,161.7,143.0,140.9,123.0,113.7,73.0,70.5,59.9,57.6,55.4,45.4,44.6,44.0,42.0,37.0,36.8,34.5,33.2,31.8,30.9,30.5,29.5,29.4,29.3,29.2,28.8,28.0,27.0,25.8,24.9,21.9,16.7,14.9,14.4,12.5.HRMS(ES)calcd[M] + for[C 39 H 62 NO4S + 640.4394,found 640.4396。
[0081] Example 7
[0082] 4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanecyclopenten-5-yl)oxy)-2-oxoethyl)thio)-1-isopropylpyridin-1-ium (e7)
[0083] White powder, yield: 51%. 1 H NMR (600MHz, DMSO-d6) δ8.91(d,J=7.3Hz,2H),8.00(d,J=7.2Hz,2H),6.09(dd,J=17.8,11.2Hz,1H),5.58 (d,J=8.3Hz,1H),5.05–4.97(m,2H),4.90–4.85(m,1H),4.57(d,J=6.0Hz,1H),4.39(d,J=7.4Hz,2H),3.42 (t,J=6.1Hz,1H),2.43(s,1H),2.19(dd,J=18.8,10.3Hz,1H),2.13–2.06(m,2H),2.04(t,J=9.0Hz,1H),1 .68–1.59(m,2H),1.56(d,J=6.7Hz,6H),1.50(d,J=3.8Hz,1H),1.37(d,J=17.2Hz,1H),1.33(s,3H),1.31–
[0084] 1.22(m,3H),1.06(s,3H),1.01(d,J=4.3Hz,1H),0.82(d,J=7.0Hz,3H),0.62(d,J=7.1Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.5,166.7,161.3,141.4,141.3,123.9,115.7,73.0,71.4,63.2,57.6,45.4,44 .6,44.0,42.0,37.0,36.8,34.5,33.7,30.6,29.1,27.0,24.9,22.7,16.6,14.9,12.0.HRMS(ES)calcd[M] + for[C 30 H 44 NO4S + ]514.2991,found514.2993.
[0085] Example 8
[0086] 4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanecyclopenten-5-yl)oxy)-2-oxoethyl)thio)-1-isobutylpyridin-1-ium (e8)
[0087] White powder, yield: 63%. 1 H NMR (600MHz, DMSO-d6) δ8.79(d,J=6.9Hz,2H),8.01(d,J=7.0Hz,2H),6.09(dd,J=17.8,11.2Hz,1H),5.58(d,J=8.3Hz,1 H),5.06–4.97(m,2H),4.57(d,J=6.0Hz,1H),4.38(s,2H),4.29(d,J=7.5Hz,2H),3.42(t,J=6.1Hz,1H),2.42(s,1H),2.1 7(d,J=6.6Hz,2H),2.12–2.01(m,3H),1.68–1.59(m,2H),1.52–1.47(m,1H),1.38(s,1H),1.33(d,J=8.2Hz,4H),1.25(d ,J=14.0Hz,2H),1.06(s,3H),1.01(d,J=4.3Hz,1H),0.87(d,J=6.6Hz,6H),0.82(d,J=7.0Hz,3H),0.61(d,J=7.1Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.6,166.6,161.4,143.1,141.4,123.6,115.7,73.0,71.4,65.9,57.6,45.4,44.6 ,44.0,42.0,37.0,36.8,34.5,33.8,30.5,30.2,29.1,27.0,24.9,19.3,16.7,14.9,12.0.HRMS(ES)calcd[M] + for[C 31 H 46 NO4S + ]528.3147, found 528.3143.
[0088] Example 9
[0089] 1-allyl-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-7-vinyldecahydro-4,9a-propanecyclopenten-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e9)
[0090] White powder, yield: 32%. 1 H NMR (600MHz, DMSO-d6) δ8.76(d,J=6.5Hz,2H),8.01(d,J=6.5Hz,2H),6.16–6.06(m,2H),5.58(d,J=8.3Hz,1H),5.42(d,J=10. 2Hz,1H),5.32(d,J=17.1Hz,1H),5.11(d,J=6.2Hz,2H),5.06–4.98(m,2H),4.57(d,J=6.0Hz,1H),4.43–4.35(m,2H),3.42(s,1 H),2.42(s,1H),2.18(d,J=10.9Hz,1H),2.07(dd,J=29.9,8.0Hz,3H),1.64(d,J=11.5Hz,2H),1.49(s,1H),1.39(s,1H),1.34 (s,3H),1.32(s,1H),1.28(d,J=12.6Hz,2H),1.06(s,3H),1.00(d,J=9.4Hz,1H),0.82(d,J=6.9Hz,3H),0.62(d,J=7.1Hz,3H). 13 CNMR(150MHz,DMSO-d6)δ217.6,166.6,161.7,143.0,141.3,132.4,123.7,121.7,115.7,73.0,71.5,57.6,55. 4,45.4,44.6,44.0,42.0,36.9,36.8,34.5,33.8,30.5,29.1,27.0,24.9,16.7,14.9,12.0.HRMS(ES)calcd[M] + for[C 30 H 42 NO4S+]512.2834,found512.2831.
[0091] Example 10
[0092] 1-(But-3-enyl)-4-[(2-{[(1S,2R,3S,4S,6R,7R,8R,14R)-3-hydroxy-2,4,7,14-tetramethyl-9-oxylidene-4-vinyltricyclo[5.4.3.01,8]tetradec-6-yl]oxy}-2-oxylideneethyl)thio]pyridin-1-ol (e10)
[0093] White solid, yield: 33%. 1 H NMR (600MHz, DMSO-d6) δ8.86–8.73(m,2H),8.03–7.95(m,2H),6.09(dd,J=17.8,11.2Hz,1H),5.77(d,J=14.3Hz,1H),5.57(d,J=8.4Hz, 1H),5.08–4.95(m,4H),4.56(d,J=9.1Hz,3H),4.38(d,J=1.6Hz,2H),3.43(t,J=6.1Hz,1H),2.65(d,J=5.4Hz,2H),2.42(s,1H),2.19(dd ,J=18.7,9.5Hz,1H),2.14–2.06(m,2H),2.04(d,J=6.7Hz,1H),1.69–1.59(m,2H),1.49(d,J=3.4Hz,1H),1.37(d,J=15.9Hz,1H),1.33( s,3H),1.29(d,J=12.6Hz,1H),1.25(d,J=13.9Hz,2H),1.06(s,3H),1.01(d,J=4.4Hz,1H),0.82(d,J=7.0Hz,3H),0.61(d,J=7.1Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.6,166.6,161.3,143.0,141.4,133.5,123.4,119.5,115.7,72.9,71.4,58.8,57.6,4 5.4,44.6,44.0,42.0,37.0,36.8,35.1,34.5,33.7,30.5,29.2,27.0,24.9,16.7,14.9,12.0.HRMS(ES)calcd[M] + for[C 31 H 44 NO4S+]526.2991, found 526.2995.
[0094] Embodiment 11
[0095] 4-[(2-{[(1S,2R,3S,4S,6R,7R,8R)-3-hydroxy-2,4,7,14-tetramethyl-9-oxylidene-4-vinyltricyclo[5.4.3.01,8]tetradec-6-yl]oxy}-2-oxylideneethyl)thio]-1-(prop-2-ynyl)pyridin-1-ol (e11)
[0096] White solid, yield: 37%. 1 H NMR (600MHz, DMSO-d6) δ8.80(dd,J=52.2,6.6Hz,2H),8.03(s,2H),6.24(d,J=6.2Hz,1H),6.09(d,J=6.7Hz,1H ),5.58(d,J=8.2Hz,1H),5.46(s,1H),5.02(dd,J=32.8,14.5Hz,2H),4.57(d,J=6.0Hz,1H),4.41(d,J=3.8Hz, 2H),3.42(s,1H),2.42(s,1H),2.18(d,J=10.8Hz,1H),2.13–2.02(m,3H),1.64(d,J=12.3Hz,2H),1.50(s,1H) ,1.35(s,5H),1.25(d,J=14.9Hz,3H),1.06(s,3H),1.01(s,1H),0.82(d,J=6.9Hz,3H),0.62(d,J=3.5Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.5,166.5,162.6,142.6,141.3,139.8,123.8,115.7,105.0,94.1,81.3,76.4,73. 0,71.5,57.6,45.4,44.6,42.0,36.9,36.8,34.5,30.5,29.1,27.0,24.9,16.7,15.0,12.0.HRMS(ES)calcd[M] + for[C 30 H 40 NO4S + ]510.2678,found 510.2675.
[0097] Example 12
[0098] 1-(But-2-ynyl)-4-[(2-{[(2R,3S,4S,6R,7R,8R,14R)-3-hydroxy-2,4,7,14-tetramethyl-9-oxylidene-4-vinyltricyclo[5.4.3.01,8]tetradec-6-yl]oxy}-2-oxylideneethyl)thio]pyridin-1-ol (e12)
[0099] White solid, yield: 43%. 1 H NMR(600MHz,Chloroform-d)δ9.05(d,J=6.4Hz,2H),7.74(d,J=6.3Hz,2H),6.30(dd,J=17.4,11.0Hz,1H),5.72(d,J=8.5Hz,1H),5.66(q,J=2.5Hz,2H),5. 24–5.22(m,1H),5.12(dd,J=17.4,1.5Hz,1H),4.00–3.83(m,2H),3.31(d,J= 6.5Hz,1H),2.27–2.17(m,2H),2.14(t,J=9.5Hz,1H),2.11–2.06(m,1H),2.06 –2.02(m,1H),1.86(t,J=2.4Hz,3H),1.70(dd,J=14.6,3.2Hz,1H),1.65–1.5 6(m,2H),1.51–1.41(m,1H),1.39(s,1H),1.38(s,2H),1.31(dd,J=17.3,2.7H z,2H),1.25(d,J=16.2Hz,1H),1.19(d,J=1.8Hz,1H),1.17(d,J=13.0Hz,1H), 1.11(s,3H),1.07–1.01(m,1H),0.82(d,J=7.0Hz,3H),0.65(d,J=7.1Hz,3H). 13 C NMR(150MHz,Chloroform-d)δ216.6,165.7,162.3,142.1,138.9,123.1,117.5,88.8,74.5,71.6,69.5,58.0,50.7 ,45.4,45.0,44.0,41.9,36.6,36.0,34.5,34.4,30.4,26.8,26.6,24.8,17.1,14.9,11.5,3.9.HRMS(ES)calcd[M] + for[C 31 H 42 NO4S + ]524.2834, found 524.2833.
[0100] Example 13
[0101] 1-(But-3-ynyl)-4-[(2-{[(1S,2R,3S,4S,6R,7R,8R,14R)-3-hydroxy-2,4,7,14-tetramethyl-9-oxylidene-4-vinyltricyclo[5.4.3.01,8]tetradec-6-yl]oxy}-2-oxylideneethyl)thio]pyridin-1-ol (e13)
[0102] White solid, yield: 72%. 1 H NMR (600MHz, DMSO-d6) δ8.83(d,J=6.6Hz,2H),8.03(s,2H),6.10(dd,J=17.8,11.2Hz,1H),5.58(d,J=8.2Hz ,1H),5.09–4.97(m,2H),4.59(d,J=6.5Hz,3H),4.40(s,2H),3.42(s,1H),3.05(s,1H),2.92(s,2H),2.42(s ,1H),2.18(d,J=10.9Hz,1H),2.07(dd,J=28.4,8.2Hz,3H),1.64(d,J=10.8Hz,2H),1.50(s,1H),1.35(d,J= 15.5Hz,5H),1.27(d,J=17.2Hz,2H),1.06(s,3H),1.01(s,1H),0.82(d,J=6.9Hz,3H),0.62(d,J=7.2Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.6,166.6,161.9,143.1,141.3,123.3,115.7,79.7,75.5,73.0,71.5,57.6,55.4,45 .4,44.6,43.3,42.0,37.0,36.8,34.5,33.8,30.9,29.2,27.0,25.4,20.6,16.7,14.9,12.0.HRMS(ES)calcd[M] + for[C 31 H 42 NO4S + ]524.2834,found 524.2831.
[0103] Embodiment 14
[0104] 1-(Carboxymethyl)-4-[(2-{[(1S,2R,3S,4S,6R,7R,8R)-3-hydroxy-2,4,7,14-tetramethyl-9-oxylidene-4-vinyltricyclo[5.4.3.01,8]tetradec-6-yl]oxy}-2-oxylideneethyl)thio]pyridin-1-ol (e14)
[0105] White solid, yield: 84%. 1 H NMR (600MHz, DMSO-d6) δ13.97(s,1H),8.75–8.72(m,2H),8.02(d,J=7.2Hz,2H),6.10(dd,J=17.8,11.2Hz,1H),5.58(d,J= 8.3Hz,1H),5.35(s,2H),5.02(d,J=15.1Hz,2H),4.57(d,J=5.9Hz,1H),4.40(d,J=6.9Hz,2H),3.42(s,1H),2.42(s,1H),2 .18(d,J=10.2Hz,1H),2.09(d,J=9.9Hz,2H),2.05(d,J=6.9Hz,1H),1.64(d,J=22.0Hz,2H),1.50(d,J=4.0Hz,1H),1.36(d ,J=15.7Hz,5H),1.28(d,J=12.6Hz,3H),1.07(s,3H),1.01(d,J=4.3Hz,1H),0.82(d,J=7.0Hz,3H),0.63(d,J=7.1Hz,3H). 13 CNMR(150MHz,DMSO-d6)δ217.5,168.2,166.5,162.9,144.6,141.3,123.1,116.3,73.0,71.5,59.9,57.6,4 5.8,44.6,44.0,42.0,36.9,36.8,34.5,33.9,30.5,29.1,27.0,24.9,16.7,15.0,12.0.HRMS(ES)calcd[M] + for[C 29 H 40 NO6S + ]530.2576,found 530.2574.
[0106] Embodiment 15
[0107] 1-(4-Carboxybutyl)-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propylcyclopentadien-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e15)
[0108] White solid, yield: 53%. 1 H NMR (600MHz, DMSO-d6) δ12.15(s,1H),8.84(d,J=6.8Hz,2H),8.00(d,J=6.8Hz,2H),6.09(dd,J=17.8,11.2Hz,1H),5.57(d,J=8.3Hz,1H),5.04 (d,J=16.1Hz,1H),5.00(d,J=11.1Hz,1H),4.57(d,J=6.0Hz,1H),4.47(t,J=7.1Hz,2H),4.38(d,J=4.2Hz,2H),3.42(t,J=6.0Hz,1H),2.42(s,1 H),2.27(t,J=7.4Hz,2H),2.22–2.16(m,1H),2.12–2.01(m,3H),1.91– 1.85(m,2H),1.65(d,J=8.4Hz,2H),1.52–1.43(m,3H),1.37(d,J=16.5H z,1H),1.34(d,J=6.1Hz,3H),1.32(s,1H),1.29–1.23(m,2H),1.06(s,3H),1.01(d,J=4.4Hz,1H),0.82(d,J=6.9Hz,3H),0.61(d,J=7.1Hz,3H). 13 CNMR(150MHz,DMSO-d6)δ217.5,174.5,166.6,161.2,143.0,141.3,123.7,115.7,73.0,71.4,59.5,57.6,45.4,44. 6,44.0,42.0,36.9,36.8,34.5,33.8,33.3,30.6,30.4,29.1,27.0,24.9,21.3,16.6,14.9,12.0.HRMS(ES)calcd[M] + for
[0109] [C 32 H 46 NO6S + ]572.3046,found 572.3043.
[0110] Example 16
[0111] 1-(5-Carboxypentyl)-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propylcyclopentadien-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e16)
[0112] White solid, yield: 23%. 1 H NMR (600MHz, DMSO-d6) δ12.04(s,1H),8.84(d,J=7.1Hz,2H),7.99(d,J=7.2Hz,2H),6.09(d,J=6.6Hz,1H),5.58(d,J =8.3Hz,1H),5.00(s,2H),4.57(d,J=6.0Hz,1H),4.45(s,2H),4.38(d,J=4.0Hz,2H),3.42(s,1H),2.41(s,1H),2.21( d,J=7.3Hz,3H),2.12–2.01(m,3H),1.87(t,J=7.6Hz,2H),1.64(d,J=9.0Hz,2H),1.52(d,J=7.7Hz,3H),1.33(s,4H), 1.32(s,1H),1.26(d,J=6.8Hz,4H),1.06(s,3H),1.01(d,J=4.4Hz,1H),0.82(d,J=7.0Hz,3H),0.62(d,J=7.1Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.5,174.7,166.6,161.1,143.0,141.4,123.6,115.7,73.0,71.4,59.6,57.6,56.8,45.4,4 4.6,44.0,42.0,36.9,36.8,34.5,33.8,30.7,30.5,29.1,27.0,25.3,24.9,24.2,16.7,14.9,12.0.HRMS(ES)calcd[M] + for[C 33 H 48 NO6S + ]586.3202, found 586.3201.
[0113] Embodiment 17
[0114] 1-(6-Carboxyhexyl)-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propylcyclopentadien-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e17)
[0115] White solid, yield: 37%. 1 H NMR (600MHz, DMSO) δ11.96(d,J=12.0Hz,1H),8.83(t,J=5.2Hz,2H),7.99(t,J =5.1Hz,2H),6.08(dt,J=11.5,7.2Hz,1H),5.57(t,J=6.4Hz,1H),5.07–4.96(m ,2H),4.60–4.55(m,1H),4.44(dd,J=12.9,5.5Hz,2H),4.41–4.34(m,2H),3.4 1(dd,J=13.1,7.1Hz,1H),2.41(d,J=7.1Hz,1H),2.19(t,J=7.4Hz,2H),2.12–2 .06(m,1H),2.06–2.00(m,1H),1.89–1.81(m,2H),1.69–1.59(m,2H),1.49(d, J=5.6Hz,2H),1.35(d,J=12.3Hz,1H),1.34–1.32(m,2H),1.31(d,J=12.7Hz,2H ),1.28(d,J=13.1Hz,2H),1.25(s,2H),1.23(s,3H),1.22(s,2H),1.05(d,J=4 .7Hz,3H),1.01(d,J=4.3Hz,1H),0.82(t,J=5.7Hz,3H),0.61(t,J=5.7Hz,3H). 13 C NMR (150MHz, DMSO) δ217.5,174.9,166.6,161.1,143.0,141.4,123.7,115.7,73.0,71.4,59.9,57.6,45.4,44.6,44. 0,42.0,37.0,36.8,34.5,34.1,33.7,30.5,29.1,29.0,28.8,27.0,25.8,24.9,16.7,14.9,12.0.HRMS(ES)calcd[M] + for[C 34 H 50 NO6S + ]600.3359,found600.3356.
[0116] Embodiment 18
[0117] 1-(7-Carboxyheptyl)-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propylcyclopentadien-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e18)
[0118] White solid, yield: 45%. 1 H NMR (600MHz, DMSO-d6) δ11.98(s,1H),8.84(d,J=6.9Hz,2H),7.99(d,J=7.1Hz,2H),6.09(d,J=6.6Hz,1H),5.57(s,1H),5.01(d,J=13.8Hz ,2H),4.58(d,J=6.0Hz,1H),4.45(s,2H),4.38(d,J=2.8Hz,2H),3.42(s,1H),3.17(d,J=4.8Hz,1H),2.41(s,1H),2.19(t,J=7.4Hz,3H),2. 10(s,1H),2.06(d,J=30.2Hz,2H),1.85(t,J=7.5Hz,2H),1.64(d,J=9.3Hz,2H),1.48(d,J=7.5Hz,3H),1.34(s,1H),1.33(s,3H),1.31(d, J=9.1Hz,2H),1.27(d,J=13.2Hz,4H),1.24–1.19(m,3H),1.06(s,3H),1.01(d,J=4.3Hz,1H),0.82(d,J=6.9Hz,3H),0.61(d,J=7.1Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.5,174.9,166.6,161.1,143.0,141.3,123.6,115.7,73.0,71.4,59.8,57.6,45.4,44.6,44.0,4 2.0,36.9,36.8,34.5,34.0,33.7,30.9,30.5,29.2,28.8,28.5,27.0,25.7,24.9,24.8,16.7,14.9,12.0.HRMS(ES)calcd[M] + for[C 35 H 52 NO6S + ]614.3515,found614.3512.
[0119] Embodiment 19
[0120] 1-(9-Carboxy)-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propylcyclopentadien-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e19)
[0121] White solid, yield: 72%. 1 H NMR (600MHz, DMSO-d6) δ11.97(s,1H),8.82(s,2H),7.99(d,J=6.5Hz,2H),6.09(d,J=6.6Hz,1H),5.57(d,J=8.3Hz,1H),5.05 –4.98(m,2H),4.58(d,J=6.0Hz,1H),4.44(s,2H),4.38(s,2H),3.42(s,1H),2.41(s,1H),2.18(s,3H),2.12–2.02(m,3H),1.8 5(s,2H),1.64(d,J=11.5Hz,2H),1.48(s,3H),1.38(td,J=13.7,3.6Hz,1H),1.34(s,1H),1.33(s,3H),1.30(s,1H),1.28(s,1 H),1.25(s,4H),1.24(s,5H),1.21(d,J=11.2Hz,2H),1.06(s,3H),1.01(s,1H),0.82(d,J=7.0Hz,3H),0.61(d,J=7.1Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.53,174.95,166.63,161.12,142.99,141.34,123.64,115.68,72.95,71.41,59.85,57.62,55.39,45.40,44.60,4 4.01,42.02,40.53,36.95,36.76,34.45,34.12,33.72,30.91,30.52, 29.15,29.08,28.96,28.79,27.00,25.78,24.92,16.66,14.93,12.01. 13C NMR(151MHz,Chloroform-d)δ216.6,165.7,162.3,142.1,138.9,123.1,117.5,88.8,74.5,71.6,69.5,58.0,50.7 ,45.4,45.0,44.0,41.9,36.6,36.0,34.5,34.4,30.4,26.8,26.6,24.8,17.1,14.9,11.5,3.9.HRMS(ES)calcd[M] + for[C 37 H 56 NO6S + ]642.3828,found 642.3825.
[0122] Embodiment 20
[0123] 1-(10-Carboxy)-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propylcyclopentadien-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e20)
[0124] White solid, yield: 24%. 1H NMR (600MHz, DMSO-d6) δ11.96(s,1H),8.83(d,J=7.2Hz,2H),7.99(d,J=7.1Hz,2H),6.09(dd,J=17.8,11.2Hz,1H),5.58(d,J=8.3Hz,1H),5.03(d,J= 16.0Hz,1H),4.99(d,J=11.2Hz,1H),4.58(d,J=6.1Hz,1H),4.44(t,J=7.2 Hz,2H),4.38(d,J=2.6Hz,2H),3.42(t,J=6.1Hz,1H),2.41(s,1H),2.18(t, J=7.4Hz,3H),2.12–2.01(m,3H),1.85(t,J=7.5Hz,2H),1.68–1.59(m,2H) ,1.51–1.45(m,3H),1.37(d,J=11.5Hz,1H),1.34(d,J=7.9Hz,3H),1.31(d ,J=5.3Hz,1H),1.28(s,2H),1.26(s,2H),1.24(s,8H),1.21(s,2H),1.06( s,3H),1.01(d,J=4.2Hz,1H),0.82(d,J=7.0Hz,3H),0.61(d,J=7.1Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.5,175.0,166.6,161.1,143.0,141.4,123.6,115.7,73.0,71.4,59.9,57.6,45.4,44.6,44.0,42.0,4 0.4,37.0,36.8,34.5,34.1,33.7,30.9,30.5,29.2,29.2,29.0,28.8,27.0,25.8,25.0,24.9,16.7,14.9,12.0.HRMS(ES)calcd[M] + for[C 38 H 58 NO6S + ]656.3985,found 656.3988.
[0125] Embodiment 21
[0126] 4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanecyclopenten-5-yl)oxy)-2-oxoethyl)thio)-1-(2-hydroxyethyl)pyridin-1-ium (e21)
[0127] White solid, yield: 38%. 1 H NMR (600MHz, DMSO-d6) δ8.72(d,J=7.0Hz,2H),7.98(d,J=7.1Hz,2H),6.10(dd,J=17.8,11.2Hz,1H),5.58(d,J=8.3Hz,1H),5.22(t,J=5.1H z,1H),5.06(d,J=17.8Hz,1H),5.00(d,J=9.4Hz,1H),4.57(d,J=6.0Hz,1H),4.50(s,2H),4.38(d,J=10.2Hz,2H),3.81(d,J=5.0Hz,2H),3.4 2(t,J=6.1Hz,1H),2.42(s,1H),2.18(d,J=9.8Hz,1H),2.13–2.02(m,3H),1.68–1.60(m,2H),1.53–1.48(m,1H),1.36(d,J=8.2Hz,3H),1.34 (s,1H),1.30(d,J=10.4Hz,1H),1.27(s,1H),1.24(s,1H),1.07(s,3H),1.01(d,J=4.3Hz,1H),0.82(d,J=7.0Hz,3H),0.63(d,J=7.1Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.5,166.6,161.2,143.4,141.3,123.2,115.8,723.0,71.5,62.2,60.4,57.6,4 5.4,44.6,44.0,42.0,37.0,36.8,34.5,33.8,30.6,29.1,27.0,24.9,16.7,15.0,12.0.HRMS(ES)calcd[M] + for[C 29 H 42 NO5S + ]516.2784, found 516.2787.
[0128] Embodiment 22
[0129] 4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propancyclopenten-5-yl)oxy)-2-oxoethyl)thio)-1-(3-hydroxypropyl)pyridin-1-ium (e22)
[0130] White solid, yield: 59%. 1 H NMR (600MHz, DMSO-d6) δ8.80(d,J=7.1Hz,2H),7.98(d,J=7.2Hz,2H),6.09(dd,J=17.8,11.2Hz,1H),5.58(d,J=8.3Hz,1H),5.04(d,J=1 6.0Hz,1H),5.00(d,J=12.9Hz,1H),4.74(t,J=4.8Hz,1H),4.57(d,J=6.1Hz,1H),4.52(t,J=7.0Hz,2H),4.38(d,J=4.7Hz,2H),3.43(d,J =5.2Hz,3H),2.42(s,1H),2.18(d,J=10.9Hz,1H),2.06(dd,J=38.2,8.3Hz,5H),1.63(d,J=22.0Hz,2H),1.50(s,1H),1.37(d,J=11.4Hz, 1H),1.34(s,3H),1.32(s,1H),1.28(d,J=12.6Hz,2H),1.06(s,3H),1.01(d,J=4.3Hz,1H),0.82(d,J=7.0Hz,3H),0.62(d,J=7.1Hz,3H). 13 C NMR (150 MHz, DMSO-d6)δ
[0131] 217.5,166.6,161.1,143.2,141.3,123.5,115.7,73.0,71.4,57.8,57.6,55.4,45.4,44.6,44.0 ,42.0,37.0,36.8,34.5,33.8,33.6,30.6,29.1,27.0,24.9,16.7,14.9,12.0.HRMS(ES)calcd[M] + for[C 30 H 44 NO5S + ]530.2940,found 530.2945.
[0132] Embodiment 23
[0133] 4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanecyclopenten-5-yl)oxy)-2-oxoethyl)thio)-1-(methoxymethyl)pyridin-1-ium (e23)
[0134] White solid, yield: 89%. 1 H NMR (600MHz, DMSO-d6) δ8.90–8.84(m,2H),8.08–8.02(m,2H),6.10(dd,J=17.8,11.2Hz,1H),5.58(d,J=8.3Hz,1H),5.08– 4.99(m,2H),4.42(d,J=3.2Hz,2H),3.52(d,J=1.2Hz,1H),3.44–3.42(m,1H),2.43(d,J=2.5Hz,1H),2.19(dd,J=18.4,9.7 Hz,1H),2.13–2.07(m,2H),2.05–2.02(m,1H),1.68–1.60(m,2H),1.52–1.48(m,1H),1.36(d,J=4.1Hz,1H),1.34(s,3H),1 .30(d,J=7.5Hz,1H),1.28–1.25(m,2H),1.24(s,2H),1.01(d,J=4.2Hz,1H),0.82(d,J=7.0Hz,3H),0.63(d,J=7.1Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.6,166.8,163.8,142.1,141.4,123.4,115.9,89.1,72.9,71.5,57.7,57.6,45 .8,44.6,44.1,42.4,37.0,36.8,34.5,33.9,30.3,29.1,26.7,24.8,16.7,14.9,12.0.HRMS(ES)calcd[M] + for[C 29 H 42 NO5S + ]516.2784,found 516.2781.
[0135] Embodiment 24
[0136] 4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanecyclopenten-5-yl)oxy)-2-oxoethyl)thio)-1-((tetrahydrofuran-2-yl)methyl)pyridin-1-ium (e24)
[0137] White solid, yield: 92%. 1H NMR (600MHz, DMSO-d6) δ8.73(d,J=7.1Hz,2H),7.98(d,J=5.8Hz,2H),6.09(d,J=5.1Hz,1H),5.58(d,J=8.3Hz,1H),5.02(d,J=13.2Hz,2H),4 .62(s,1H),4.57(d,J=6.0Hz,1H),4.38(s,2H),4.20(d,J=7.2Hz,1H),3.80(d,J=7.0Hz,1H),3.67(d,J=7.4Hz,1H),2.42(s,1H),2.18(d,J= 10.3Hz,1H),2.09(d,J=10.5Hz,2H),2.04(d,J=7.0Hz,2H),1.85(d,J=2.9Hz,2H),1.65(s,1H),1.61(s,2H),1.50(s,1H),1.36(s,2H),1.34 (s,3H),1.30(d,J=11.2Hz,1H),1.26(s,2H),1.24(s,2H),1.06(s,3H),1.01(d,J=4.3Hz,1H),0.82(d,J=7.0Hz,3H),0.62(d,J=5.1Hz,3H). 13 C NMR (150MHz, DMSO-d6) δ217.6,166.6,161.4,143.5,141.4,123.2,115.7,77.4,73.0,72.0,68.1,62.7,57.6,45.4 ,44.6,44.0,42.0,40.5,37.0,36.8,34.5,33.8,30.5,29.1,27.0,25.9,24.9,16.7,14.9,12.0.HRMS(ES)calcd[M] + for[C 32 H 46 NO5S + ]556.3097,found556.3094.
[0138] Embodiment 25
[0139] 4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanecyclopenten-5-yl)oxy)-2-oxoethyl)thio)-1-(4-methylbenzyl)pyridin-1-ium (e25)
[0140] White solid, yield: 43%. 11H NMR (600 MHz, Chloroform-d) δ 9.02 (d, J = 6.2 Hz, 2H), 7.64 (d, J = 6.0 Hz, 2H), 7.40 (d, J = 7.7 Hz, 2H), 7.12 (d, J = 7.6 Hz, 2H), 6.26 (d, J = 6.4 Hz, 1H), 5.92 (s, 2H), 5.68 (d, J = 8.5 Hz, 1H), 5.16 (d, J = 11.0 Hz, 1H), 5.05 (d, J = 17.4 Hz, 1H), 3.84 (d, J = 28.9 Hz, 2H), 3.29 (d, J = 6.5 Hz, 1H), 2.27 (s, 3H), 2.21 (s, 1H), 2.19 (s, 1H), 2.12 (d, J = 9.6 Hz, 1H), 2.10 (s, 2H), 2.03 (s, 1H), 2.02 (s, 1H), 1.69 (d, J = 14.6 Hz, 1H), 1.59 (d, J = 13.7 Hz, 2H), 1.41 (d, J = 15.1 Hz, 1H), 1.37 (s, 1H), 1.34 (s, 3H), 1.30–1.27 (m, 1H), 1.24 (d, J = 29.3 Hz, 1H), 1.16 (d, J = 32.4 Hz, 1H), 1.07 (s, 3H), 1.05 (d, J = 4.5 Hz, 1H), 0.80 (d, J = 7.0 Hz, 3H), 0.61 (d, J = 7.1 Hz, 3H). 13 13C NMR (150 MHz, Chloroform-d) δ 216.7, 165.7, 161.4, 142.7, 140.1, 138.8, 130.4, 123.0, 129.5, 123.1, 117.4, 74.5, 71.5, 63.1, 58.0, 45.4, 45.0, 44.0, 41.8, 36.6, 36.0, 34.5, 34.4, 30.9, 30.3, 26.5, 24.8, 21.3, 17.5, 14.8, 11.5. HRMS (ES) calcd + for 35 C 46 H + NO4S
[0141] Example 26
[0142] 1-{[4-(2-cyanophenyl)phenyl]methyl}-4-[(2-{[(1S,2R,3S,4S,6R,7R,8R,14R)-3-hydroxy-2,4,7,14-tetramethyl-9-oxylidene-4-vinyltricyclo[5.4.3.01,8]tetradec-6-yl]oxy}-2-oxylideneethyl)thio]pyridin-1-ol (e26)
[0143] White solid, yield: 65%. 1 H NMR (600MHz, DMSO-d6) δ9.02(d,J=7.2Hz,2H),8.05(d,J=7.2Hz,2H),7.97(d,J=6.7Hz,1H),7.81(t,J=7.7Hz,1H),7.65(d,J=7.6Hz,3H) ,7.62(d,J=6.8Hz,3H),6.08(d,J=6.6Hz,1H),5.56(d,J=8.3Hz,1H),5.02(d,J=16.0Hz,1H),4.96(d,J=12.9Hz,1H),4.56(d,J=6.0Hz,1 H),3.40(t,J=6.1Hz,1H),2.38(d,J=2.5Hz,1H),2.16(d,J=8.6Hz,1H),2.10–2.01(m,3H),1.64(s,2H),1.47(d,J=3.8Hz,1H),1.37(s,1 H),1.33(d,J=6.8Hz,1H),1.30(s,1H),1.29(s,3H),1.25(s,1H),1.24(s,2H),0.99(s,1H),0.81(d,J=7.0Hz,3H),0.59(d,J=7.1Hz,3H). 13 C NMR (150 MHz, DMSO-d6)δ
[0144] 217.5,166.6,162.1,144.1,143.1,141.3,139.1,135.6,134.4,134.1,130.6,130.0,129.2,129.1,124.1,118.9,115.7,110.6,7 3.0,71.5,62.0,57.6,45.4,44.6,44.0,42.0,36.9,36.7,34.4,33.8,30.5,29.1,27.0,24.9,16.7,14.9,12.0.HRMS(ES)calcd[M] + for[C 41 H 47 N2O4S +]663.3265, found 663.3262.
[0145] Embodiment 27
[0146] 4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propancyclopenten-5-yl)oxy)-2-oxoethyl)thio)-1-(4-methoxybenzyl)pyridin-1-ium (e27)
[0147] White solid, yield: 53%. 1 H NMR (600MHz, DMSO-d6) δ8.96(d,J=6.8Hz,2H),7.99(d,J=6.9Hz,2H),7.51(d,J=8.7Hz,2H),6.98(d,J=8.7Hz,2H),6.06(d,J=6.6Hz,1H ),5.63(s,2H),5.54(d,J=8.3Hz,1H),4.97(d,J=21.7Hz,2H),4.60(d,J=6.1Hz,1H),4.36(d,J=3.3Hz,2H),3.75(s,3H),3.39(s,1H),2 .35(s,1H),2.19(d,J=8.2Hz,1H),2.09(d,J=9.5Hz,1H),2.01(d,J=5.6Hz,2H),1.63(d,J=4.2Hz,2H),1.47(s,1H),1.35(d,J=16.5Hz, 1H), 1.29 (d, J = 3.6Hz, 1H), 1.26 (s, 3H), 1.24 (s, 2H), 1.03 (s, 3H), 1.00 (d, J = 4.4Hz, 1H), 0.81 (d, J = 7.0Hz, 3H), 0.57 (d, J = 7.1Hz, 3H). 13 C NMR (150 MHz, DMSO-d6)δ
[0148] 217.9,166.6,161.6,160.4,142.7,141.3,130.8,127.1,124.0,115.7,115.0,73.4,71.4,62.0,57.6,55.7, 45.4,44.6,44.0,42.0,36.9,36.7,34.4,33.8,30.5,29.1,27.0,24.9,16.6,14.9,12.0.HRMS(ES)calcd[M] + for[C 35 H 46 NO5S+ ]592.3097,found592.3094.
[0149] Embodiment 28
[0150] 1-(4-(tert-Butyloxycarbonyl)benzyl)-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-3-oxo-7-vinyldecahydro-4,9a-propanecyclopentadien-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e28)
[0151] White solid, yield: 43%. 1 H NMR (600MHz, CDCl3) δ9.18(d,J=6.5Hz,2H),7.90(d,J=8.1Hz,2H),7.64(s,2H),7.62(d,J=8.2Hz,2H),6.26(d,J=6.4Hz,1H),6.18(s,2 H),5.68(d,J=8.5Hz,1H),5.16(d,J=12.4Hz,1H),5.06(d,J=17.4Hz,1H),3.83(d,J=23.7Hz,2H),3.29(d,J=6.5Hz,1H),2.18(d,J=9.8H z,2H),2.12(d,J=9.6Hz,1H),2.02(t,J=8.1Hz,2H),1.68(d,J=11.4Hz,1H),1.59(s,1H),1.50(s,9H),1.39(t,J=12.1Hz,2H),1.34(s, 3H),1.28(d,J=16.2Hz,2H),1.22–1.16(m,2H),1.06(d,J=11.0Hz,3H),1.05–0.99(m,1H),0.80(d,J=7.0Hz,3H),0.61(d,J=7.1Hz,3H). 13 C NMR (150MHz, CDCl3) δ216.6,165.5,164.8,161.8,143.0,138.5,137.0,133.4,130.6,129.3,123.1,117.4,81.7,74.4,71.6, 62.3,58.0,45.4,45.0,44.0,41.8,36.6,36.4,36.0,34.4,30.3,28.1,26.8,26.6,24.8,17.0,14.8,11.5.HRMS(ES)calcd[M] + for[C 39 H 52 NO6S+ ]662.3515,found662.3518.
[0152] Embodiment 29
[0153] 1-(3-((tert-Butyloxycarbonyl)amino)benzyl)-4-((2-(((3aR,4R,5R,7S,8S,9R,9aS,12R)-8-hydroxy-4,7,9,12-tetramethyl-7-vinyldecahydro-4,9a-propanecyclopentadien-5-yl)oxy)-2-oxoethyl)thio)pyridin-1-ium (e29)
[0154] White solid, yield: 71%. 1 H NMR(600MHz,Chloroform-d)δ9.18(d,J=6.5Hz,2H),7.90(d,J=8.1Hz,2H),7.64(s,2H),7.62(d,J=8.2Hz,2H),6.26(d,J=6.4Hz,1H), 6.18(s,2H),5.68(d,J=8.5Hz,1H),5.16(d,J=12.4Hz,1H),5.06(d,J=17.4Hz,1H),3.83(d,J=23.7Hz,2H),3.29(d,J=6.5Hz,1H),2.18 (d,J=9.8Hz,2H),2.12(d,J=9.6Hz,1H),2.04–2.00(m,2H),1.68(d,J=11.4Hz,1H),1.62–1.56(m,2H),1.50(s,10H),1.43–1.36(m,2H) ,1.34(s,3H),1.28(d,J=16.2Hz,2H),1.22–1.16(m,2H),1.07(s,3H),1.05–0.99(m,1H),0.80(d,J=7.0Hz,3H),0.61(d,J=7.1Hz,3H). 13 C NMR(150MHz,Chloroform-d)δ216.6,165.5,164.8,161.8,143.0,138.5,137.0,133.4,130.6,129.3,123.1,117.4,81.7,74.4,71 .6,62.3,58.0,45.4,45.0,44.0,41.8,36.6,36.4,36.0,34.4,30.3,28.1,26.8,26.6,24.8,17.0,14.8,11.5.HRMS(ES)calcd[M] + for[C 39 H 53N2O6S + ]677.3624,found677.3626.
[0155] 1. Study on the antibacterial activity of pleuromutilin derivatives
[0156] 1.1 Minimum inhibitory concentration determination
[0157] Experimental method: The bacteria stored at -80℃ were dissolved at room temperature, streaked on LB agar plates, cultured for 16 hours, single colonies were picked and inoculated into MHB liquid culture medium, cultured for 16 hours, the bacterial solution was streaked on LB agar plates, cultured for 16 hours, single colonies were picked and inoculated into MHB broth again, the bacterial solution was diluted to OD600=0.5, and stored for later use.
[0158] Accurately weigh 12.8 mg of the compound and tiamulin, dissolve them in 1 mL of DMSO solution respectively, add 9 mL of sterile water, mix well, take 1 mL of the drug solution and add 9 mL of sterile water thereto, the final concentration of the drug solution is 128 μg / mL (1% DMSO), and store for later use.
[0159] In this experiment, compounds e1-e29 were selected as the research objects. According to the regulations of the Clinical Laboratory Standards Committee (CLSI) of the United States, tylosin was used as the control drug to determine the minimum inhibitory concentration of Gram-positive bacteria (Staphylococcus aureus, MRSA, Streptococcus pneumoniae, MRSE, Bacillus subtilis, Enterococcus faecium) and Gram-negative bacteria (Klebsiella pneumoniae, Escherichia coli, Proteus). 100 μL of tylosin was added to all columns 1-12 of a sterile 96-well plate. MHB broth, add 100 μL of prepared drug solution (128 μg / mL) to the first column, mix with a dispenser, take 100 μL from each well of the first column and add to the second column, mix with a dispenser, take 100 μL from each well of the second column and add to the third column, mix with a dispenser, repeat the operation to the 12th column, take out 100 μL of liquid from each well of the 12th column and discard it, make two parallel controls for each compound, and divide the drug solution concentrations from the first to the 12th columns of the 96-well plate into the following table: The concentrations of the drugs were 64 μg / mL, 32 μg / mL, 16 μg / mL, 8 μg / mL, 4 μg / mL, 2 μg / mL, 1 μg / mL, 0.5 μg / mL, 0.25 μg / mL, 0.125 μg / mL, 0.0625 μg / mL and 0.03125 μg / mL respectively. The 96-well plate was placed in a 37°C incubator for 16 hours to determine the minimum drug concentration that completely inhibited bacterial growth in the wells.
[0160] Table 1 Antibacterial activity of compound e1-29 (minimum inhibitory concentration, MIC, μg / mL)
[0161]
[0162]
[0163] 1.2 Antimicrobial activity and structure-activity relationship analysis
[0164] As shown in Table 1 above, the antibacterial activity of these compounds against several standard bacterial strains was tested. They generally showed moderate antibacterial activity against Staphylococcus aureus, Pneumococcus, MRSA and MRSE. Except for e17, compounds with carboxylic acid structures (e14-e20) showed poor antibacterial activity, which may be due to the formation of salt bridges between the anions of the carboxylic acid and the pyridinium cation structure, preventing them from binding to the target site.
[0165] Compounds e4, e11, e12 and e27 showed higher antibacterial activity than tylosin against Staphylococcus aureus, Streptococcus pneumoniae, MRSA and MRSE. The introduction of hydrophobic structure into the side chain of thymosin showed weak to moderate antibacterial activity (minimum inhibitory concentration, MICs = 0.0625-8 μg / mL). Compound e4 showed excellent inhibitory activity against Staphylococcus aureus ATCC 25923, MRSA ATCC 43300, MRSE ATCC 51625, Streptococcus pneumoniae ATCC 49619 and Klebsiella pneumoniae CMCC (B) 46117 at low concentrations, which was 2-16 times lower than tylosin.
[0166] Compound e4 showed excellent inhibitory effects on MRSA and MRSE at low concentrations (0.0625 μg / mL), which were 8 and 4 times lower than those of tiamulin, respectively. The antibacterial activity of compound e4 against Bacillus subtilis, Enterococcus faecium and Klebsiella pneumoniae was significantly higher than that of tiamulin.
[0167] The above results indicate that appropriate lipid solubility and smaller lipid-water partition coefficient are more conducive to improving the antibacterial activity of pleuromutilin derivatives, which may be related to their ability to better bind to biological targets.
[0168] 1.3 Antimicrobial activity against antibiotic-resistant bacteria
[0169] The present invention explores the antibacterial activity of e4 against multidrug-resistant bacteria. The drug sensitivity paper test shows that compound e4 is active against most resistant strains, including strains that can express the erm, cfr and lsaA genes for resistance to pleuromutilin drugs (Table 2). Compound e4 overcomes the drug resistance mediated by the erm gene expressed by Staphylococcus aureus and Streptococcus pneumoniae, and its minimum inhibitory concentration is 16-64 times lower than that of tylosin (Table 2). Similarly, compound e4 overcomes the drug resistance to hydrophilic quinolones (such as norfloxacin, enoxacin, ofloxacin and ciprofloxacin) mediated by the combination of norR, norA and MgrA genes. Compound e4 is different from other pleuromutilin derivatives in that it shows antibacterial activity against resistant Gram-negative bacteria, Escherichia coli and Klebsiella pneumoniae, with a minimum inhibitory concentration of 2-16 μg / mL.
[0170] Table 2 In vitro antibacterial activity of compound e4
[0171]
[0172] 1.4 Study on time sterilization curve
[0173] To study the antibacterial activity of compound e4 in vitro, a time-kill curve test was performed. The test used clinically isolated Staphylococcus aureus strains carrying multiple resistance genes and phenotypes (S. aureus-sa1: a clinically isolated resistant Staphylococcus aureus that shows strong resistance to erythromycin, chloramphenicol, ampicillin, streptomycin, tylosin and doxycycline) and MRSA. The two bacterial strains were inoculated in MHB broth, cultured at 37°C for 16 hours, and then diluted to 10 6 CFUs / mL, add different concentrations of compound e4 to make the final concentration of e4 0.5×, 1×, 3× and 6×MIC. Sample the culture medium at different time points and dilute the samples by 10-fold dilution method. The diluted samples are evenly spread on MHA plates. Each group of experiments is repeated three times. The plates are placed in a 37°C incubator for 16 hours and the number of colonies is counted.
[0174] like Figure 1 The results of the test of e4 against MRSA (ATCC 43300) and multidrug-resistant Staphylococcus aureus are shown in Figure 2. The 6×MIC of e4 reduced the number of MRSA and multidrug-resistant Staphylococcus aureus to 2-3 log within 8 hours. 10 CFU / mL. Compound e4 at 6×MIC treated MRSA, and the number of MRSA was reduced to 2 log within 8 hours 10 CFU / mL, but the bacterial count in the 3×MIC compound e4 treatment group was reduced by 2-3log 10CFU / mL. For multidrug-resistant Staphylococcus aureus, compound e4 showed significant inhibitory effect at 1×MIC, and e4 significantly reduced the number of bacteria by 100 times at a concentration of 0.5×MIC within 8 hours. However, the tylosin group only killed bacteria at a concentration of 6×MIC (MIC=128μg / mL), and the concentration difference between compound e4 and tylosin was only 96 times (the MIC of compound e4 was 8μg / mL). This result shows that e4 has a stronger inhibitory effect on multidrug-resistant bacteria, and the rapid bactericidal effect will reduce the probability of bacteria becoming resistant to antibiotics, shorten the treatment time, and increase the clinical potential of compound e4.
[0175] 1.5 Induced resistance studies
[0176] To evaluate the spontaneous resistance of e4, an induced resistance assay was performed using tiamulin as a positive control.
[0177] according to Figure 2 The test results showed that the MIC value of compound e4 against MRSA increased 8 times within 24 days, while the MIC value of tylosin increased 64 times, and similar results were observed for Klebsiella pneumoniae. According to the test results, the isolated resistant MRSA strains had no cross-resistance (Table 3), and the resistant MRSA showed sensitivity to e4 with a MIC of 0.5μg / mL. MRSA resistant to compound e4 was continuously passaged in ordinary broth culture medium, and the MIC of e4 was restored to 0.5μg / mL. The results showed that e4 hardly develops resistance.
[0178] Table 3 Cross-antibacterial activity test of compound e4 and tylosin against drug-resistant bacteria (MIC, μg / mL)
[0179]
[0180]
[0181] a MRSA resistant to compound e4. b MRSA resistant to tiamulin.
[0182] 1.6 Post-antibiotic effect (PAE) and post-antibiotic sub-MIC effect (PA-SME) studies
[0183] Post-antibiotic effect (PAE) and post-antibiotic sub-MIC effect (PA-SME) are important indicators for evaluating antimicrobial drugs.
[0184] For the study of compound e4, the strain used in this experiment was MRSA.
[0185] PAE test method: set up three groups of 0×, 2× and 4× MIC. MRSA was inoculated into MHB broth and cultured overnight for 16 hours. Three portions of the cultured broth were diluted to 10 9 CFU / mL, compound e4 was added to the broth, and the final concentrations of e4 were 0×, 2× and 4×MIC, respectively, and cultured at 37°C on a shaker for 1 hour. 1mL of broth was taken from each group and added to 9mL of sterile broth for 10-fold dilution. The dilution was repeated three times. This step was to reset the system, and this time was counted as 0 hours. The bacterial solution was diluted from each group at 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, and 8h, and spread on MHA agar plates. The plates were placed in a 37°C incubator for 16h and counted. Each sampling and plating was repeated three times.
[0186] PA-SME test method: Before resetting the system, two experimental groups were set up: 2×MIC and 4×MIC. MRSA was inoculated into MHB broth and cultured overnight for 16 hours. Three aliquots of the cultured broth were taken and diluted to ~10 9 CFU / mL, compound e4 was added to the broth, the final concentration of e4 was 2× and 4×MIC, respectively, and the culture was shaken at 37℃ for 1h. Take 1mL of broth from each group, add it to 9mL of sterile broth and mix it for 10-fold dilution, repeat the dilution three times, prepare two tubes for each group, add compound e4 to the prepared broth, so that the concentration of compound e4 in the broth is 0.25×MIC and 0.5×MIC, respectively. This step is to reset the system. After resetting the system, there are four groups, and this time is counted as 0h. Take bacterial solution from each group at 0h, 1h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, 9h, and 10h, dilute it, spread it on MHA agar plate, place it in a 37℃ incubator for 16h, and count it. Each sampling and plating is repeated three times.
[0187] like Figure 3 As shown, the PAE of MRSA treated with 2×MIC and 4×MIC concentrations of e4 were 2.308 hours and 2.535 hours, respectively. This result shows that compound e4 has a better post-antibiotic effect, and the difference in PAE between 4×MIC and 2×MIC is small, indicating that compound e4 has a similar rapid efflux rate. The PA-SME of 4×MIC and 2×MIC were 2.753 hours and 2.622 hours, respectively, which also means that MRSA treated with 0.5×MIC concentration of e4, when treated again with 2×MIC, the inhibition time was extended to about 2.7 hours.
[0188] 1.7 Study on the effect of antibiotics on bacterial migration ability
[0189] The present invention uses a swimming exercise experiment to study the effect of e4 on bacterial activity: agar plates (1% trypsin, 0.5% sodium chloride and 0.3% agar) containing different concentrations of compound e4 are prepared, Escherichia coli, Staphylococcus aureus, MRSA, MRSE, wild Staphylococcus and Proteus are selected for the test, the above strains are inoculated into MHB broth and cultured for 16 hours, each bacterial solution is diluted with MHB to OD600=0.5, 1 μL of the bacterial solution is taken and added to the center of agar plates with different concentrations of e4, the agar plates are placed in a 37°C incubator and cultured for 48 hours, and the diameter of the colony is measured with a vernier caliper.
[0190] like Figure 4 , Compound e4 at 1×MIC concentration significantly inhibited bacterial migration ability compared to negative control. At 2-4×MIC concentrations, swimming and swarming were significantly reduced for all tested isolates compared to controls without antibiotics.
[0191] 1.8 Mouse systemic infection model and in vivo efficacy
[0192] Given the good in vitro antibacterial activity of e4 against multidrug-resistant bacteria, we tested its in vivo activity using multidrug-resistant Staphylococcus aureus-sa1 in the BABL / C mouse intraperitoneal infection model.
[0193] The experiment used Kunming mice of SPF level weighing 18-22g to test the in vivo drug activity of compound e4. The strain selected was multidrug-resistant Staphylococcus aureus, and tylosin was selected as the control drug.
[0194] Compound e4 was dissolved in 5% DMSO, 30% PEG300 and sterile PBS buffer and stored for later use. Multidrug-resistant Staphylococcus aureus was inoculated into MHB broth and cultured at 37°C for 16 hours. Centrifuged at 5000 rpm for 10 min, the precipitate was collected and re-dissolved with sterile PBS buffer, and the number of bacteria was determined by agar plate counting method. The mice were grouped after one week of normal feeding. The drugs e4 and tylosin were set at 0 mg / kg, 2.5 mg / kg, 5 mg / kg, 10 mg / kg, 20 mg / kg, and 40 mg / kg, respectively, for a total of 10 groups, with 6 mice in each group, half male and half female. On the first day of the experiment, 150 mg / kg of cyclophosphamide was administered, and 100 mg / kg of cyclophosphamide was administered after four days of normal feeding. At the same time, food was cut off at night. According to the results of the preliminary experiment, 10 9 CFU / mL of bacteria were inoculated into the mouse peritoneal cavity. One hour after the injection of bacteria, the mice were intraperitoneally injected with drugs according to the dosage of each group. The 0 mg / kg group was given normal saline and the mice were fed continuously. The death time and number of mice were counted, and the ED of the mice was calculated by statistical analysis. 50 value.
[0195] like Figure 5 As shown, 10 mg / kg of compound e4 showed a significant protective effect (66%), while 40 mg / kg of tiamulin had a weaker protective effect, with a survival rate of 50% against S. aureus-sa1. Treatment with e4 and tiamulin showed a dose-dependent protective effect and resulted in different survival rates of mice, ED 50 The results showed that compound e4 has a better inhibitory effect than tilmiline in vivo, indicating that compound e4 can be an effective antibacterial agent.
[0196] To further evaluate the in vivo efficacy of e4, bacterial loads in the lungs and livers of infected mice were examined 2 days after treatment with e4 and tiamulin ( Figure 5 (C and D) At 40 and 20 mg / kg of e4, the multidrug-resistant Staphylococcus aureus load in the lungs was reduced by 4.17 and 3.29 log10 CFU / mL, respectively, while 40 and 20 mg / kg of tilmiline resulted in a reduction in bacterial load of 1.94 and 1.35 log10 CFU / mL, respectively.
[0197] Since Staphylococcus aureus is an important pathogen of pulmonary infection, we further evaluated the mitigation effect of compound e4 on MRSA-induced lung tissue damage. Figure 6 As shown. Lung tissues of mice treated with 40 mg / kg tiamulin showed obvious thickening of alveolar septa and slight neutrophil infiltration compared with the 40 mg / kg e4 group. In contrast, lung histology of mice treated with 20 mg / kg tiamulin showed thickening of alveolar septa, congestion of pulmonary capillaries, and infiltration of lymphocytes and neutrophils.
[0198] 2. Study on the antibacterial mechanism of pleuromutilin derivatives
[0199] 2.1 GFP protein inhibition test
[0200] Staphylococcus aureus expressing GFP was cultured to mid-logarithmic phase and collected by centrifuge. The cells were then collected by centrifugation and resuspended in PBS buffer. The Staphylococcus aureus suspension and e4 (1×MIC, 4×MIC) were incubated at 37°C for 1 hour. The cells were then collected by centrifugation. After resuspension in PBS buffer, imaging was performed using a fluorescence microscope.
[0201] Scanning electron microscope (SEM) image ( Figure 7Figures AE) show that compound e4 at a concentration of 1×MIC mainly induced bacterial fragmentation, while at a concentration of 4×MIC, e4 inhibited bacterial growth, induced bacterial cell membrane perforation, and inhibited bacterial division. In contrast, the positive control drug tylosin mainly inhibited bacterial division at both concentrations.
[0202] We used Staphylococcus aureus expressing GFP to verify the inhibitory effect of e4 on the protein. Compared with the control group, e4 effectively inhibited the expression of GFP, thereby reducing the green fluorescence intensity ( Figure 7 FJ). By counting bacteria, we also found that the number of bacteria was significantly reduced after 1 hour of treatment with 1×MIC and 4×MIC of compound e4. This result indicates that e4 can effectively interfere with the expression of bacterial proteins.
[0203] Based on the SEM results, o-nitrophenyl-β-D-galactoside (ONPG) was used to assess the integrity of the cell membrane. Normally, ONPG cannot enter the bacteria through the cell membrane. When the cell membrane is penetrated, ONPG enters the bacteria and interacts with β-galactosidase to produce o-nitrophenol. Figure 6 As shown in Figure K, e4 induces bacterial cell wall perforation, thereby producing a large amount of o-nitrophenol (the maximum absorption peak of o-nitrophenol is 415 nm). This result shows that bacterial perforation is related to the concentration of compound e4.
[0204] 2.2DAPI / PI fluorescence staining study
[0205] The antibacterial effect on the cell membrane was detected using 4',6-diamidino-2-phenylindole (DAPI) and propidium iodide (PI) fluorescent dye staining: S. aureus in MHB was washed with PBS buffer and then diluted to 1×108 CFU / mL with PBS buffer. The S. aureus suspension and e4 (1×, 3×, and 6× MIC) were incubated at 37°C. DAPI and PI (final concentrations of 10μg / mL and 20μg / mL) were added to the bacterial suspension after 2 hours. The bacterial suspension was then incubated in the dark for 50 minutes. The cells were then collected by centrifuge and washed twice with PBS buffer. After resuspension with PBS buffer, imaging was performed using a fluorescence microscope.
[0206] The study further confirmed the ability of compound e4 to damage bacterial cell membranes. DAPI is a DNA-specific probe with blue fluorescence. PI only produces strong red fluorescence on damaged cell membranes, which can be used to monitor membrane integrity. Figure 8As shown, Staphylococcus aureus was treated with different concentrations of compound e4. Compared with the bacteria in the tiamulin-treated group, the e4-treated group showed moderate red fluorescence, indicating that e4 destroyed the bacterial cell membrane. This result further shows that high concentrations of e4 can not only inhibit the synthesis of bacterial proteins, but also destroy the bacterial cell membrane.
[0207] 3. Safety Assessment of Pleuromutilin Derivatives
[0208] 3.1 Cytotoxicity and hemolytic toxicity analysis
[0209] Cytotoxicity assay:
[0210] This experiment used HEK293T and HEPG2 cells with complete growth vitality. The cells were counted using a cell counting plate. Dosage groups of 7.5 μg / mL, 15 μg / mL, 30 μg / mL, 60 μg / mL, 120 μg / mL, 250 μg / mL, 500 μg / mL, and 1000 μg / mL were set. Approximately 10 5 Cells of different densities were inoculated into 96-well plates and cultured at 37°C for 24 hours. The culture medium was removed and then 100 μL of culture medium was added. 10 μL of compound e4 was added to make the concentration of e4 in each group reach the dose concentration. The cells were incubated for 6 hours and then 10 μL of CCK-8 working solution was added. After incubation at 37°C for 4 hours, the culture medium was detected at 450 nm using an ELISA reader.
[0211] Hemolytic toxicity test:
[0212] Rabbit erythrocytes were centrifuged at 2000 rpm for 5 minutes and washed three times with PBS. Compound e4 at different concentrations was added to rabbit erythrocytes reconstituted in PBS. 1% Triton X-100 solution and PBS were used as positive and negative controls, respectively. The samples were placed at 37°C, incubated for 5 minutes, and centrifuged again (2000 rpm, 5 minutes). The supernatant was taken and the absorbance was measured at 450 nm using an ELISA reader.
[0213] Cytotoxicity assays were performed using human hepatocellular carcinoma (HEPG2) and human embryonic kidney (HEK293) cells. CCK-8 assays showed that compound e4 showed no signs of cytotoxicity at concentrations up to 60 μg / mL ( Fig. 9 Compound e4 and tiamulin were similarly toxic to both cell types.
[0214] Since pyridinium cationic compounds can hemolyze, we explored the hemolytic effect of e4 on erythrocytes. Compound e4 showed a hemolytic rate of less than 14% at 200 μg / mL, and its MIC value was only 0.063 μg / mL ( Fig. 9C). The hemolysis of MRSA on rabbit red blood cells after co-culture with different concentrations of e4 was tested. The results are shown in Fig. 9 In D, the supernatant hemoglobin levels of the 0.25×, 0.5×, and 1× MIC groups were lower than those of the control group. Compound e4 inhibited the production of α-hemolysin by MRSA in a concentration-dependent manner. Compared with the control group, the absorbance of the 0.25×, 0.5×, and 1× MIC groups decreased by 25%, 34%, and 93%, respectively.
[0215] 3.2 Oral acute toxicity test in mice
[0216] To study the safety of e4 in vivo, we performed an oral toxicity study using BABL / C mice.
[0217] The experiment used 60 SPF-grade Kunming mice weighing 18-22g. The mice were kept in an environment with a 12-hour light and 12-hour dark cycle and were given sufficient food and clean drinking water. The 60 mice were randomly divided into six groups, and each group of mice was given 1000mg / kg, 750mg / kg, 500mg / kg, 250mg / kg, 125mg / kg and 0mg / kg of compound e4, respectively. The death of the mice was observed and recorded for 14 days.
[0218] The results showed that the survival rate of mice treated with 631 mg / kg was over 80% within 14 days ( Fig. 9 (E) LD determined by Bliss 50 The value is 879 mg / kg. In vivo and in vitro toxicity tests showed that e4 has very low toxicity.
[0219] In summary, the present invention screened out a series of pleuromutilin derivatives with good activity and synthesized new pleuromutilin derivatives with pyridinium cations. Most of the compounds generally showed good antibacterial activity against Gram-positive cocci (Klebsiella pneumoniae, MRSA, MRSE, Staphylococcus aureus and resistant bacteria), Escherichia coli MG1655 and Escherichia coli MG1655ΔacrB in vitro. Compound e4 is the most effective drug against Gram-positive and Gram-negative bacteria, especially Staphylococcus aureus and multidrug-resistant Staphylococcus aureus. By testing the drug resistance of bacteria to compound e4, no obvious drug resistance was found after continuous induction. In addition, e4 has obvious antibacterial activity against various resistant bacteria.
[0220] The results of the GFP protein inhibition test showed that the binding mode of e4 to PTC was similar to that of lefamulin, indicating that e4 can inhibit bacterial protein synthesis. Scanning electron microscopy, o-nitrophenyl-β-galactoside test and PI showed that compound e4 can destroy the bacterial cell wall. These experiments show that e4 kills bacteria through the above two different mechanisms of action.
[0221] A mouse systemic infection model showed that ED in mice infected with multidrug-resistant Staphylococcus aureus 50 It is 5.68 mg / kg. At the same time, in vivo and in vitro toxicity tests showed that the toxicity of e4 is very low. The truncated pleuromutilin derivative e4 can be used as a lead compound for further optimization and discovery of new antibiotics.
[0222] The above specific implementation manner cannot be used as a limitation on the protection scope of the present invention. For those skilled in the art, any substitution, improvement or change made to the implementation manner of the present invention falls within the protection scope of the present invention.
[0223] The matters not described in detail in the present invention are all known technologies to those skilled in the art.
Claims
1. A pleuromutilin derivative having the following general structural formula (I): in, R is X is 1.
2. A method for synthesizing the pleuromutilin derivative according to claim 1, characterized in that: The steps include: (1) Synthesis of pleuromutilin derivative intermediates S1. Synthesis of intermediate compound b Accurately weigh 7.57 g of pleuromutilin, add it to 25 mL of methyl tert-butyl ether, add 4.2 g of 4-toluenesulfonyl chloride while stirring, add 5 mL of 10 M NaOH solution to the above solution to obtain a mixture; stir the above mixture at 60° C. for 1 hour and then quickly cool it to 0° C. to obtain a white suspension; wash it with methyl tert-butyl ether and water respectively, and dry it to obtain a white solid; S2. Synthesis of intermediate compound c: 111 mg of 4-mercaptopyridine was added to 1 mL of methanol solution, and 40 mg of NaOH was added to the above solution. After stirring at room temperature, 3 mL of dichloromethane solution containing 585 mg of compound b was added, and the mixture was stirred at room temperature for 24 hours. The pH of the solution was adjusted to 6, and the mixture was concentrated under reduced pressure. Ethyl acetate was added to redissolve the mixture, and saturated sodium chloride was added to wash the extracted mixture, and the mixture was dried over anhydrous sodium sulfate. The organic phase was concentrated and purified by column chromatography; (2) Synthesis of pleuromutilin derivative e4 1 mmol of compound c and 1 mmol of linker RX were stirred and refluxed in 10 mL of acetonitrile solution. After the reaction was completed, the mixture was concentrated under reduced pressure, 10 mL of ethyl acetate was added to dissolve it again, saturated sodium chloride was added to wash and extract, and the mixture was dried over anhydrous sodium sulfate. The concentrated crude product was purified by column chromatography to obtain the pleuromutilin derivative as described in claim 1; wherein the linker RX is 1-iodoheptane; 3. Use of the pleuromutilin derivative according to claim 1 in the preparation of a drug for preventing and / or treating multidrug-resistant bacterial infection diseases, characterized in that: The bacteria are Staphylococcus aureus, MRSA, Streptococcus pneumoniae, MRSE, Bacillus subtilis, Enterococcus faecium, Klebsiella pneumoniae, Escherichia coli, and Proteus.
Citation Information
Patent Citations
Pleuromutilin derivative with pathogenic microorganism resistant activity and pyridine quaternary ammonium salt side chain as well as preparation method and application of pleuromutilin derivative
CN114736194A
Pleuromutilin derivative having 2-amino phenyl mercaptan side chain as well as preparation method and application thereof
US20190135742A1
